Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 7/20 | 0.66 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259706 | 0.88 | MEN1 (0.77) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL2126663 | 0.88 | MEN1 (0.71) | MEN1KMT2ARAB9ANPC1TP53 | |
| SCHEMBL7234095 | 0.87 | MEN1 (0.71) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL5604593 | 0.86 | KMT2A (0.69) | MEN1KMT2ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL7238124 | 0.86 | MEN1 (0.79) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL8461683 | 0.85 | MEN1 (0.73) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL14363224 | 0.85 | MEN1 (0.73) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL29434800 | 0.85 | KCNK3 (0.87) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL259468 | 0.85 | KCNK3 (0.87) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL29672230 | 0.85 | PTGS1 (0.74) | MEN1KMT2ARAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0213572-A1 | 3-and 4-amino-N(alkyl phenyl) benzamide compounds and composition containing same as anticonvulsant drugs | Research Corporation Technologies, Inc. (a Delaware corp.) (US) | 1987-03-11 | — | — | EP | claimed |
| WO-2023040793-A1 | ANTI-INFLAMMATORY COMPOUND AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-03-23 | — | — | WO | disclosed |
| WO-2014183300-A1 | VEGFR TYROSINE KINASE INHIBITORS | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO., LTD. (CN) | 2014-11-20 | — | — | WO | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | MEN1 1490/4885KMT2A 1060/4885RXFP1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.